Whittier Trust CO Cytom X Therapeutics, Inc. Transaction History

Whittier Trust CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	SELL	$1.21 - $5.13 $5,328 - $22,592	-4,404 Reduced 66.69%	2,200 $2,000
Q3 2023 Oct 27, 2023	SELL	$1.26 - $1.87 $2,216 - $3,289	-1,759 Reduced 21.03%	6,604 $8,000
Q2 2022 Jul 28, 2022	SELL	$1.53 - $2.89 $4,046 - $7,644	-2,645 Reduced 24.03%	8,363 $15,000
Q3 2018 Oct 23, 2018	SELL	$18.04 - $26.41 $39,778 - $58,234	-2,205 Reduced 16.69%	11,008 $204,000
Q2 2018 Jul 27, 2018	BUY	$21.38 - $29.68 $282,493 - $392,161	13,213 New	13,213 $302,000
Q2 2018 Jul 20, 2018	SELL	$21.38 - $29.68 $282,493 - $392,161	-13,213 Closed	0 $0
Q1 2018 May 01, 2018	BUY	$21.76 - $34.22 $287,514 - $452,148	13,213 New	13,213 $376,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Whittier Trust CO, based on Form 13F filings with the SEC.

Stay updated on Whittier Trust CO with notifications on news.